Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126807301 | 12680730 | 1 | I | 20160816 | 20160824 | 20160824 | EXP | IT-CELLTRION INC.-2016IT007990 | CELLTRION | GANZETTI G; CAMPANATI A; SIMONETTI O; GIULIODORI K; GIANGIACOMI M; LEMME G AND OFFIDANI A. USE OF INFLIXIMAB IN TOXIC EPIDERMAL NECROLYSIS:A STILL OPENED CHALLENGE. ITALIAN JOURNAL OF DERMATOLOGY VENEREOLOGY. 2015;150:467-71 | 0.00 | Y | 0.00000 | 20160824 | MD | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126807301 | 12680730 | 1 | PS | Infliximab | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | 5 MG/KG, DAILY | U | U | 125544 | 5 | MG/KG | POWDER FOR SOLUTION FOR INFUSION | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126807301 | 12680730 | 1 | Toxic epidermal necrolysis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126807301 | 12680730 | DE |
| 126807301 | 12680730 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126807301 | 12680730 | Off label use | |
| 126807301 | 12680730 | Pneumonia | |
| 126807301 | 12680730 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |